Showing results (1-10 of 107) with videos related to
Sort By:
Pageof 11
Hematology/Oncology Clinics of North America|November 30, 2013
Balancing risks and benefits of therapy for patients with favorable-risk limited-stage Hodgkin lymphoma: the role of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy aloneAnnette E Hay, Ralph M MeyerLeukemia & Lymphoma|July 10, 2024
Development and testing of a lymphoma clinical trial-specific frailty index: a secondary analysis of the NCIC-CTG LY.12 clinical trialAbi Vijenthira, Xinzhi Li, Michael Crump, et al.European Journal of Cancer (Oxford, England : 1990)|September 5, 2015
Correlation of single arm versus randomised phase 2 oncology trial characteristics with phase 3 outcomeJose G Monzon, Annette E Hay, Gail T McDonald, et al.European Journal of Haematology. Supplementum|July 13, 2005
Is there convincing evidence for the use of chemotherapy alone in patients with limited stage Hodgkin's lymphoma?Ralph M MeyerCurrent Oncology (Toronto, Ont.)|April 3, 2021
Evaluating the Indirect Costs of Care Associated with Salvage Chemotherapy for Relapsed and Refractory Aggressive-Histology Lymphoma: A Subset Analysis of the Canadian Cancer Trials Group (CCTG) LY.12 Clinical TrialAnca Prica, Annette E Hay, Michael Crump, et al.Current Oncology (Toronto, Ont.)|April 3, 2021
A Canadian Prospective Study of Linkage of Randomized Clinical Trial to Cancer and Mortality Registry DataAnnette E Hay, Nicole Mittmann, Michael Crump, et al.Hematology. American Society of Hematology. Education Program|November 25, 2006
The management of patients with limited-stage classical Hodgkin lymphomaMary K Gospodarowicz, Ralph M MeyerHematology. American Society of Hematology. Education Program|December 13, 2012
Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapyRalph M Meyer, Richard T HoppeBlood|July 24, 2012
Point/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapyRalph M Meyer, Richard T HoppePageof 11